TQB3911

TQB3911 · Chia Tai Tianqing Pharmaceutical Group; Nanjing Shunxin Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TQB3911, covering 2024-11-04 to 2024-11-04. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia [Phase 1]

See pricing